Key result
Targeting gut microbiota dysbiosis shows therapeutic potential against doxorubicin-induced cardiotoxicity.
Why the study?
Doxorubicin cardiotoxicity is a major limitation lacking effective therapy, prompting interest in gut microbiota strategies to prevent or attenuate cardiac injury.
Does gut microbiota modulation prevent or attenuate doxorubicin-induced cardiotoxicity?
Does gut microbiota modulation prevent or attenuate doxorubicin-induced cardiotoxicity?
Targeting the gut microbiota represents a promising experimental strategy to attenuate doxorubicin-induced cardiotoxicity and subsequent heart failure.
Should not yet change doxorubicin management; leaves open whether microbiota modulation attenuates cardiotoxicity in trials.
Doxorubicin is a widely used chemotherapy for the treatment of several types of cancer. However, its application is restricted due to adverse effects, particularly cardiotoxicity, which can progress to heart failure-a chronic and debilitating condition. Several mechanisms have been identified in the pathophysiology of doxorubicin-induced cardiotoxicity, including oxidative stress, mitochondrial dysfunction, inflammation, and disruption of collagen homeostasis. More recently, dysbiosis of the gut microbiota has been implicated in the development and perpetuation of cardiac injury. Studies have reported alterations in the composition and abundance of the microbiota during doxorubicin treatment. Therefore, as of recent, there is a new field of research in order to develop strategies involving the gut microbiota to prevent or attenuate cardiotoxicity since there is no effective therapy at the moment. This narrative review aims to provide an update on the role of gut microbiota and intestinal permeability in the pathophysiology of cardiovascular diseases, and more specifically doxorubicin-induced cardiotoxicity. Additionally, it seeks to establish a foundation for future research targeting gut microbiota to alleviate cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Tonon et al. (2025) conducted a review in Doxorubicin-induced cardiotoxicity. Gut microbiota modulation was evaluated. Gut microbiota dysbiosis and intestinal barrier disruption are implicated in doxorubicin-induced cardiotoxicity, and modulating the microbiota may offer a potential therapeutic strategy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: